Advice You
#1 in Business Subscribe Email Print

You are here: Home > Business > Marketing > Who Will Buy SCO?

Tags

  • facing
  • interesting
  • linux market
  • vested interest
  • linux market

  • Links

  • Apartment Realty Advisors in Brandon Florida
  • Allergies-How To Deal With Summertime Triggers
  • Turn Your Small Business Website into a Marketing Machine!
  • Advice You - Who Will Buy SCO?

    For the last year I have monitored the declining financial condition of SCO as they bleed away cash on both ill-advised litigation and ill-conceived produc
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    ts. In the past week various news organizations have belatedly followed my lead, speculating on when SCO's death knell will sound.

    Given the financial ine
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    itability of SCO's demise, the more interesting question is "who might buy SCO?" Lord knows SCO is a cheap stock, running just north of a buck per share th
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    s afternoon and facing delisting if it sinks much further. With a market cap of a measly $23M, any one of a number of players could gobble it up in an inst
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    nt. If there is any meat on SCO's bones, it may be a race to see which vulture picks the carcass clean.

    So who would buy this corpse, and to what end? On
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    the chessboard of marketing, there are some interesting gambits.

    Red Hat - The King: The recent (un)holy alliance between Novell and Microsoft, wit
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    h their unwritten threats of litigation against other Linux distributions and developers, gives Red Hat motive. SCO claims copyrights to much of the UNIX f
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    undation, and hence to (allegedly) much of Linux. If Red Hat were slick and fast, they could procure SCO, liberate the copyrights, publish and mirror the k
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    y information, and throw Novell and Microsoft's newfound advantage into a meat grinder. There are legal dangers therein, but this litigious front is so lit
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    ered now that this action would take years to resolve, and in the mean time earn Red Hat top honors among Open Source advocates around the globe. Fast shuf
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    le this plan through any of the non-profit (and hence expendable) Open Source organization, and it might be a risk-free adventure.

    Novell - The Queen:
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    b> Novell has a vested interest in acquiring SCO and any supposed claims they have to UNIX. By bringing home what was once entirely theirs, Novell would mu
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    tiply the leverage they already possess and make the Novell/Microsoft F.U.D. machine even more fearsome. This one trick might well knock a leg out from und
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    r Red Hat, and make Larry Ellison wince.

    Oracle - The Rook: Ellison knows a gambit when he sees one, and is not shy when it comes to using the cour
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    s to push an issue (as he did by going up against the FTC during his Peoplesoft plunder). Larry now has a vested interest in keeping Red Hat propped-up, es
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    ecially since the Novell/Microsoft pairing is beginning to show serious traction. Since Larry wants to make money from Red Hat's work, and keep Microsoft o
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    n the server-side decline, he must slow any progress Novell makes in the Linux market. "Owning" some rights to UNIX/Linux gives him a means to that end.

    <
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    >IBM - The Knight: Since IBM is now the champion of all things Open, they may chose to be a white knight. IBM could buy SCO from petty cash, and public
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    y indemnify anyone contributing to Linux by holding alleged title to SCO intellectual property. This helps keep the Linux market competitive by maintaining
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    equality between two main vendors. IBM does not want Linux to slip into a one-company product, and they want to please the Open Source community.

    Any bets


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.adviceyou.org.ua/article/26354/adviceyou-Who-Will-Buy-SCO.html">Who Will Buy SCO?</a>

    BB link (for phorums):
    [url=http://www.adviceyou.org.ua/article/26354/adviceyou-Who-Will-Buy-SCO.html]Who Will Buy SCO?[/url]

    Related Articles:

    Teaching Jobs

    Water Heaters

    Ten Ideas for Marketing Your New Business and Website

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com

    pozycjonowanie www gov.darkseo.pl/podmiot-terapii.html codowny blog andrzeja gov.darkseo.pl/podmiot-funduszu.html poker bonus